← Human Trials & Peer-Reviewed Studies
Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial.
Plain-language guide to PMID 22052313 (2011): double-blind randomized controlled trial of Follistatin-344 in 26 subjects.
Key Facts
- PMID
- 22052313
- Journal
- Journal of drugs in dermatology : JDD
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Zimber MP et al. (11 authors)
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Follistatin-344.
All 26 subjects tolerated the single, intradermal injection of HSC procedures well, and no signs of an adverse reaction were reported.
Histopathological evaluation of the treatment site biopsies taken at 22 and 52 weeks post-treatment revealed no abnormal morphology, hamartomas, or other pathological responses.
Who Took Part
The study group was 26 subjects.
The age groups tagged for this paper are teenagers, young adults, adults and middle-aged adults, men only.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.
Random assignment meant chance, not the researchers, decided who got Follistatin-344 and who got the comparison, which limits bias.
Blinding on both sides kept the subjects and researchers unaware of who received Follistatin-344.
Some subjects received a placebo instead of Follistatin-344, giving a reference point.
It is described as a pilot, a small early test of whether a larger Follistatin-344 study would be practical.
What Was Measured
Histopathological evaluation of the treatment site biopsies taken at 22 and 52 weeks post-treatment revealed no abnormal morphology, hamartomas, or other pathological responses.
The subject headings attached to it are Alopecia, Bioengineering, Fibroblast Growth Factor 7, Follistatin, Injections, Intradermal, Pilot Projects and Vascular Endothelial Growth Factor A.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Follistatin-344 in 26 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2011 (Journal of drugs in dermatology : JDD), a journal based in United States.
More context: the Follistatin-344 compound page, all human trials.
Our Notes on the Compound
Follistatin-344: A myostatin- and activin-binding protein studied in gene-therapy trials for muscular dystrophy; black-market vials have been found mislabeled.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.